title: Karyotype changes during long-term targeted therapy of chronic myeloid leukemia with imatinib.
abstract: The main risk factors during imatinib therapy of chronic myeloid leukemia are still subject to discussion. A group of 39 patients was cytogenetically examined and monitored before and during long-term treatment with imatinib. The cytogenetic response was investigated using karyotype analysis and fluorescence in situ hybridisation method. Different therapy effects were shown for three subgroups distinguished before the start of treatment: patients with the sole translocation t(9;22) with a typical pattern of BCR/ABL fusion vs. patients with submicroscopic deletion in the fusion region ABL/BCR of the sole t(9;22) vs. patients with aberrations additional to t(9;22) and without submicroscopic deletion. Of the two group with sole t(9;22) the group with deletion in the ABL/BCL region suffered a poorer treatment outcome than the group without deletion. The risk of progression of cytogenetic changes in group with deletion was more than nine times higher than in patients with sole t(9;22) without deletion (statistically significant).
authors.affiliation: Cytogenetics Laboratory, The Marie Sklodowska-Curie Institute of Oncology, Warsaw, Poland. barpien@coi.waw.pl
authors.forename: Barbara
authors.initials: B
authors.lastname: Pieńkowska-Grela
authors.forename: Jolanta
authors.initials: J
authors.lastname: Rygier
authors.forename: Renata
authors.initials: R
authors.lastname: Woroniecka
authors.forename: Beata
authors.initials: B
authors.lastname: Grygalewicz
authors.forename: Anna
authors.initials: A
authors.lastname: Pastwińska
authors.forename: Paulina
authors.initials: P
authors.lastname: Krawczyk
authors.forename: Bernadeta
authors.initials: B
authors.lastname: Ceglerek
authors.forename: Ilona
authors.initials: I
authors.lastname: Seferyńska
authors.forename: Anna
authors.initials: A
authors.lastname: Sikorska
authors.forename: Lech
authors.initials: L
authors.lastname: Konopka
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D001549:Benzamides; D002872:Chromosome Deletion; D002892:Chromosomes, Human, Pair 22 / Q000235:genetics; D002899:Chromosomes, Human, Pair 9 / Q000235:genetics; D018450:Disease Progression; D005260:Female; D016044:Fusion Proteins, bcr-abl / Q000235:genetics; D006801:Humans; D000068877:Imatinib Mesylate; D017404:In Situ Hybridization, Fluorescence; D007621:Karyotyping; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000235:genetics* / Q000473:pathology; D008297:Male; D010879:Piperazines / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D012307:Risk Factors; D013997:Time Factors; D014178:Translocation, Genetic; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D016044:Fusion Proteins, bcr-abl